Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Neuroscience ; 141(1): 521-31, 2006 Aug 11.
Article in English | MEDLINE | ID: mdl-16697115

ABSTRACT

Functional recovery following intrastriatal transplantation of fetal dopaminergic neurons in animal models of Parkinson's disease is, at least in part, dependent on the number of surviving dopaminergic neurons and the degree of graft-derived dopaminergic reinnervation of the host striatum. In the present study, we analyzed whether continuous exposure of glial cell line-derived neurotrophic factor (GDNF) to mature dopaminergic grafts could further boost the functional outcome of widespread intrastriatal dopaminergic grafts. Rats with dopamine-denervating lesions received multiple intrastriatal transplants of fetal dopaminergic cells and graft-induced behavioral effects were analyzed in drug-induced and spontaneous motor behaviors. At three months after grafting, animals received intrastriatal injections of recombinant lentiviral vectors encoding for either human GDNF or the green fluorescent protein. Continuous exposure of GDNF to the grafts did not boost the functional recovery beyond what was observed in the control animals. Rather, in some of the spontaneous motor behaviors, animals in the GDNF-group showed deterioration as compared with control animals, and this negative effect of GDNF was associated with a down-regulation of the tyrosine hydroxylase enzyme. Based on these and our earlier results, we propose that intrastriatal administration of GDNF at the time of or shortly after grafting is highly effective in initially promoting the cell survival and fiber outgrowth from the grafts. However, once the grafts are mature, GDNF's ability to boost dopaminergic neurotransmission follows the same dynamics as for the native nigral dopaminergic neurons, which appears to be dependent on the concentration of GDNF. Since rather low doses of glial cell line-derived neurotrophic factor at nanogram levels appear to saturate these effects, it may be critical to adjust GDNF levels using tightly regulated gene expression systems.


Subject(s)
Cell Transplantation/methods , Dopamine/metabolism , Glial Cell Line-Derived Neurotrophic Factor/administration & dosage , Motor Activity/drug effects , Parkinson Disease/drug therapy , Parkinson Disease/surgery , Analysis of Variance , Animals , Apomorphine/pharmacology , Behavior, Animal , Cell Count/methods , Corpus Striatum/cytology , Corpus Striatum/metabolism , Corpus Striatum/transplantation , Disease Models, Animal , Drug Interactions , Female , Green Fluorescent Proteins/metabolism , Motor Activity/physiology , Neurons/drug effects , Neurons/metabolism , Psychomotor Performance/drug effects , Psychomotor Performance/physiology , Rats , Rats, Sprague-Dawley , Recovery of Function/drug effects , Recovery of Function/physiology , Rotarod Performance Test/methods , Transplants , Tyrosine 3-Monooxygenase/metabolism , Vesicular Monoamine Transport Proteins/metabolism
2.
Gene Ther ; 13(12): 966-73, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16511527

ABSTRACT

Lentiviral vectors are promising tools for CNS gene transfer since they efficiently transduce the cells of the nervous system in vivo. In this study, we have investigated the transduction efficiency of lentiviral vectors pseudotyped with Ross River virus glycoprotein (RRV-G) (RRV-G-pseudotyped lentiviral vectors (RRV-LV)). The RRV is an alphavirus with an extremely broad host range, including the cells of the central nervous system. Previous studies have shown that lentiviral vectors can be efficiently pseudotyped with this envelope protein and have demonstrated promising features of such vectors, including the possibility to establish stable producer cell lines. After injection of RRV-LV expressing green fluorescent protein into different structures in the rat brain we found efficient transduction of both neurons and glial cells. By using two cell-type-specific promoters, neuron-specific enolase and human glial fibrillary acidic protein, we demonstrated cell-specific transgene expression in the desired cell type. Ross River virus glycoprotein-pseudotyped lentiviral vectors also transduced human neural progenitor cells in vitro, showing that receptors for the RRV-G are present on human neural cells.


Subject(s)
Central Nervous System Diseases/therapy , Genetic Therapy/methods , Genetic Vectors/genetics , Glycoproteins/genetics , Lentivirus/genetics , Neurons/metabolism , Ross River virus/genetics , Transduction, Genetic/methods , Viral Proteins/genetics , Animals , Blotting, Western/methods , Cell Line , Female , Gene Expression , Genetic Vectors/administration & dosage , Green Fluorescent Proteins/genetics , Hippocampus/metabolism , Humans , Injections , Rats , Rats, Sprague-Dawley , Stem Cells/metabolism , Substantia Nigra/metabolism , Transfection/methods
3.
Exp Neurol ; 170(1): 36-47, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11421582

ABSTRACT

The physiological interrelationships between cognitive impairments, neurotransmitter loss, amyloid processing and energy metabolism changes in AD, cholinergic dementia and Down's syndrome are largely unknown to date. This report contains novel studies into the association between cognitive function and cerebral metabolism after long-term selective CNS cholinergic neuronal and synaptic loss in a rodent model. We measured local cerebral rates of glucose utilization ((14)C-2-deoxyglucose) throughout the brains of awake rats 4.5 months after bilateral intraventricular injections of a cholinotoxic antibody directed against the low-affinity NGF receptor (p75 NGF) associated with cholinergic neurons (192 IgG-saporin). Permanent cholinergic synapse loss was demonstrated by [(3)H]-vesamicol in vitro autoradiography defining presynaptic vesicular acetylcholine (ACh) transport sites. While other metabolic studies have defined acute and transient glucose use changes after relatively nonspecific lesions of anatomical regions containing cholinergic neurons, our results show sustained reductions in glucose utilization in brain regions impacted by cholinergic synapse loss, including frontal cortical and hippocampal regions, relative to glucose use levels in control rats. In the same animals, impaired cognitive spatial performance in a Morris water maze was correlated with reduced glucose use rates in the cortex and hippocampus at this time point, which is consistent with increased postmortem cortical and hippocampal amyloid precursor protein (APP) levels (45, 46). These results are consistent with the view of cholinergic influence over metabolism, APP processing, and cognition in the cortex and hippocampus.


Subject(s)
Alzheimer Disease/physiopathology , Antibodies, Monoclonal/administration & dosage , Cerebral Cortex/metabolism , Cognition Disorders/physiopathology , Hippocampus/metabolism , Immunotoxins/administration & dosage , Neurons/metabolism , Synapses/metabolism , Alzheimer Disease/chemically induced , Alzheimer Disease/complications , Animals , Autoradiography , Behavior, Animal/drug effects , Cerebral Cortex/drug effects , Cholinergic Agents/administration & dosage , Cognition Disorders/chemically induced , Cognition Disorders/complications , Deoxyglucose/pharmacokinetics , Disease Models, Animal , Female , Glucose/metabolism , Hippocampus/drug effects , In Vitro Techniques , Injections, Intraventricular , Maze Learning/drug effects , N-Glycosyl Hydrolases , Neurons/drug effects , Piperidines/pharmacokinetics , Rats , Rats, Sprague-Dawley , Receptor, Nerve Growth Factor , Receptors, Nerve Growth Factor/antagonists & inhibitors , Ribosome Inactivating Proteins, Type 1 , Saporins , Synapses/drug effects , Wakefulness
4.
Eur J Neurosci ; 13(8): 1589-99, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11328352

ABSTRACT

Here we studied the effects of glial cell line-derived neurotrophic factor (GDNF) in a rat model that represents the symptomatic stages of Parkinson's disease. GDNF was infused starting 2 weeks after an intrastriatal 6-hydroxydopamine (6-OHDA) lesion in order to halt the ongoing degeneration of the nigrostriatal dopaminergic neurons. GDNF or vehicle was infused in the striatum or the lateral ventricle via an osmotic minipump over a total 4-week period (2-6 weeks postlesion). Motor function was evaluated by the stepping, paw reaching and drug-induced motor asymmetry tests before the pump infusion was initiated, and was repeated once during (5 weeks postlesion) and twice after the withdrawal of the minipumps (7 and 11 weeks postlesion). We found that within two weeks following the lesion approximately 40% of the nigral TH-positive neurons were lost. In the vehicle infusion groups there was an additional 20% cell loss between 2 and 12 weeks after the lesion. This latter cell loss occurred mainly in the caudal part of the SN whereas the cell loss in the rostral SN was almost complete within the first two weeks. Ventricular GDNF infusion completely blocked the late degenerating neurons in the caudal SN and had long lasting behavioural effects on the stepping test and amphetamine rotation, extending to 6 weeks after withdrawal of the factor. Striatal infusion affected the motor behaviour transiently during the infusion period but the motor performance of these animals returned to baseline upon cessation of the GDNF delivery, and the delayed nigral cell loss was marginally affected. We conclude that intraventricular GDNF can successfully block the already initiated degenerative process in the substantia nigra, and that the effects achieved via the striatal route, when GDNF is given acutely after the lesion, diminish as the fibre terminal degeneration proceeds.


Subject(s)
Motor Activity/drug effects , Nerve Growth Factors , Nerve Tissue Proteins/pharmacology , Parkinson Disease/physiopathology , Amphetamine/pharmacology , Animals , Corpus Striatum/enzymology , Corpus Striatum/pathology , Dopamine/metabolism , Female , Glial Cell Line-Derived Neurotrophic Factor , Infusion Pumps , Injections, Intraventricular , Nerve Degeneration/chemically induced , Nerve Degeneration/pathology , Oxidopamine , Parkinson Disease/pathology , Parkinson Disease, Secondary/chemically induced , Rats , Rats, Sprague-Dawley , Rotation , Stereotyped Behavior/physiology , Substantia Nigra/drug effects , Substantia Nigra/metabolism , Time Factors , Tyrosine 3-Monooxygenase/metabolism
5.
Brain Res ; 886(1-2): 82-98, 2000 Dec 15.
Article in English | MEDLINE | ID: mdl-11119690

ABSTRACT

During the last few years, recombinant viral vectors derived from adenovirus (Ad), adeno-associated virus (AAV) or lentivirus (LV) have been developed into highly effective vehicles for gene transfer to the adult central nervous system. In recent experiments, in the rat model of Parkinson's disease, all three vector systems have been shown to be effective for long-term delivery of glial cell line-derived neurotrophic factor (GDNF) at biologically relevant levels in the nigrostriatal system. Injection of the GDNF encoding vectors into either striatum or substantia nigra thus makes it possible to obtain a regionally restricted over-expression of GDNF within the nigrostriatal system that is sufficient to block the toxin-induced degeneration of the nigral dopamine neurons. Injection of GDNF vectors in the striatum, in particular, is effective not only in rescuing the cell bodies in the substantia nigra, but also in preserving the nigrostriatal projection and a functional striatal dopamine innervation in the rat Parkinson model. Long-term experiments using AAV-GDNF and LV-GDNF vectors show, moreover, that sustained GDNF delivery over 3-6 months can promote regeneration and significant functional recovery in both 6-OHDA-lesioned rats and MPTP-lesioned monkeys. The impressive efficacy of the novel AAV and LV vectors in rodent and primate Parkinson models suggests that the time may now be ripe to explore these vector systems as tools for neuroprotective treatments in patients with Parkinson's disease.


Subject(s)
Gene Transfer Techniques , Genetic Therapy/methods , Genetic Vectors/administration & dosage , Nerve Growth Factors , Nerve Tissue Proteins/administration & dosage , Parkinson Disease, Secondary/therapy , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine , Adenoviridae/genetics , Adenoviridae/immunology , Animals , Cell Survival/drug effects , Corpus Striatum/drug effects , Corpus Striatum/metabolism , Corpus Striatum/pathology , Dependovirus/genetics , Disease Models, Animal , Gene Expression , Genetic Vectors/adverse effects , Genetic Vectors/genetics , Genetic Vectors/metabolism , Glial Cell Line-Derived Neurotrophic Factor , Haplorhini , Inflammation/etiology , Inflammation/immunology , Lentivirus/genetics , Microinjections , Nerve Tissue Proteins/biosynthesis , Nerve Tissue Proteins/genetics , Oxidopamine , Parkinson Disease, Secondary/chemically induced , Parkinson Disease, Secondary/metabolism , Rats , Substantia Nigra/drug effects , Substantia Nigra/metabolism , Substantia Nigra/pathology , Treatment Outcome
6.
Proc Natl Acad Sci U S A ; 96(21): 12108-13, 1999 Oct 12.
Article in English | MEDLINE | ID: mdl-10518584

ABSTRACT

A number of in vitro studies have shown that activation of muscarinic receptors by cholinergic agonists stimulates the nonamyloidogenic, alpha-secretase-processing pathway of amyloid precursor protein (APP). To determine whether increased cholinergic neurotransmission can modify the APP processing in vivo, we administered a muscarinic receptor agonist (RS86) to normal or aged rats and rats with severe basal forebrain cholinergic deficits (induced by 192 IgG-saporin). The levels of the cell-associated APP in neocortex, hippocampus, and striatum, as well as the secreted form of APP (APPs) in cerebrospinal fluid, were examined by Western blots. Additionally, we investigated the association between the altered APP levels and behavioral deficits caused by cholinergic lesions. We found that treatment with muscarinic receptor agonist resulted in decreased APP levels in neocortex and hippocampus and increased levels of APPs in cerebrospinal fluid. Regulation of APP processing by the muscarinic agonist treatment occurred not only in normal rats, but also in aged and cholinergic denervated rats that model this aspect of Alzheimer's disease. Interestingly, we found that elevation of APP in neocortex correlated with the cognitive deficits in water-maze testing of rats with cholinergic dysfunction. These data indicate that increased cholinergic neurotransmission can enhance nonamyloidogenic APP processing in intact and lesioned rats and that APP may be involved in cognitive performance.


Subject(s)
Amyloid beta-Protein Precursor/metabolism , Cognition , Muscarinic Agonists/metabolism , Receptors, Muscarinic/metabolism , Aging , Amyloid beta-Protein Precursor/cerebrospinal fluid , Animals , Antibodies, Monoclonal/pharmacology , Behavior, Animal/physiology , Blotting, Western , Cerebral Cortex/metabolism , Cholinergic Agents/pharmacology , Corpus Striatum/metabolism , Escape Reaction/physiology , Female , Hippocampus/metabolism , Immunotoxins/pharmacology , Male , Maze Learning , N-Glycosyl Hydrolases , Parasympathomimetics/pharmacology , Rats , Rats, Inbred F344 , Rats, Sprague-Dawley , Ribosome Inactivating Proteins, Type 1 , Saporins , Succinimides/pharmacology
7.
Med Pregl ; 46 Suppl 1: 77-9, 1993.
Article in English | MEDLINE | ID: mdl-8569616

ABSTRACT

In order to reevaluate effectiveness of iodine prophylaxis in Macedonia, epidemiological, ultrasonographic studies and estimation of urine excretion were performed. The results from the epidemiological survey in nongoitrogenic regions demonstrated goiter between 12.8% and 18%. Much higher prevalence of goiter was found in goitrogenic regions, between 20.8% and 60.8%. The incidence of goiter increased with age, and its prevalence is higher in girls when compared with the boys of the same age group. The thyroid volume estimated by ultrasonography was higher in children from goitrogenic regions when compared to nongoitrogenic. There was a good correlation between ultrasonographic volumetry data and size of the thyroid estimated by palpation. Urinary iodine excretion demonstrated low values in children from goitrogenic regions as indicator of iodine deficiency.


Subject(s)
Goiter, Endemic/prevention & control , Iodine/therapeutic use , Adolescent , Child , Female , Goiter, Endemic/diagnostic imaging , Goiter, Endemic/epidemiology , Humans , Male , Republic of North Macedonia/epidemiology , Ultrasonography
9.
Cancer ; 45(2): 340-4, 1980 Jan 15.
Article in English | MEDLINE | ID: mdl-7351014

ABSTRACT

Aspiration biopsies were performed on 1536 patients with goiter who showed scintigraphically "cold" nodules. Twelve among them had clinical and cytological positive diagnosis. The remaining 1524 patients had aspiration biopsies without suspicion of the malignant nature of their goiters. Among them, 45 patients had a positive or suspect cytological diagnosis. Fourteen had not been yet operated on. Thirty-one were operated on and 28 malignancies were confirmed histologically. In three patients, cytological diagnosis was false positive. The remaining patients were cytologically negative. Thirty-seven were operated on and four false negative cases were found. The application of aspiration biopsy on every patient with a cold thyroid nodule resulted in the detection and very early diagnosis of clinically unsuspected thyroid neoplasms, the great majority of which were confined to the gland itself without metastasic spread. This fact makes the prognosis better. In addition, it is probable that the early detection of differentiated thyroid neoplasms and their surgical ablation interrupt their natural course towards anaplastic carcinoma, with its grim prognosis.


Subject(s)
Thyroid Neoplasms/diagnosis , Adult , Aged , Biopsy, Needle , Cytodiagnosis , False Negative Reactions , False Positive Reactions , Goiter, Nodular/diagnosis , Goiter, Nodular/diagnostic imaging , Humans , Middle Aged , Radionuclide Imaging , Risk , Thyroid Neoplasms/diagnostic imaging
SELECTION OF CITATIONS
SEARCH DETAIL
...